Araris Biotech
Latest round
- Series A
Last raised
- Oct 2022
Total raised
- $41M
Investors
- 9
About Araris Biotech
Founded in 2019 and headquartered in Zurich, Switzerland, Araris Biotech AG specializes in developing novel antibody-drug conjugate technology. The company was founded by Philipp Spycher.000 mn based on milestone achievements.Araris Biotech AG specializes in the development of proprietary antibody-drug conjugate (ADC) technology, particularly their innovative AraLinQ™ linker platform. This technology facilitates the rapid and efficient attachment of drug payloads to off-the-shelf antibodies in a single step, eliminating the need for re-engineering antibodies. The primary function of these ADCs is to deliver highly potent anti-cancer drugs directly to targeted diseased tissues while minimizing harm to healthy cells. Their product offerings aim to address critical problems associated with existing ADC technologies, such as poor stability, high heterogeneity, and limited solubility.Araris Biotech AG generates revenue primarily through strategic partnerships and research agreements with leading pharmaceutical companies, including notable collaborations with Taiho Pharmaceutical and Johnson & Johnson. These partnerships often involve licensing agreements for the use of Araris' proprietary technology in developing next-generation ADCs. The structure of these transactions typically consists of upfront payments, milestone payments based on development progress, and potential royalties on future sales of commercialized products.Araris Biotech AG's recent acquisition by Taiho Pharmaceutical is expected to enhance its oncology portfolio through the integration of its ADC technology.000 mn from the TRADE SALE to expand its research efforts and develop new ADC products. Additionally, Araris aims to penetrate new markets in Asia, particularly targeting growth in Japan and South Korea, with plans to launch innovative ADC therapies by 2026. The strategic direction is geared towards enhancing collaborations and increasing the scale of operations to meet the global demand for advanced cancer therapies.
Who invested in Araris Biotech
9 investors across 3 rounds
See all investors in Araris Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Araris Biotech
Who invested in Araris Biotech?
Araris Biotech has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Araris Biotech raised?
Araris Biotech has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Araris Biotech last raise money?
Araris Biotech's most recent round on record is a Series A, in Oct 2022.
What does Araris Biotech do?
Founded in 2019 and headquartered in Zurich, Switzerland, Araris Biotech AG specializes in developing novel antibody-drug conjugate technology.
Where is Araris Biotech headquartered?
Araris Biotech is headquartered in Zurich, Switzerland.
Which VCs invest in companies like Araris Biotech?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Araris Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Araris Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.